Correo Electrónico
DNINFOA - SIA
Bibliotecas
Convocatorias
Identidad U.N.
Publicado
Clinical questionnaires for chronic obstructive pulmonary disease diagnosis: A systematic review and meta-analysis
Cuestionarios clínicos para el diagnóstico de la enfermedad pulmonar obstructiva crónica. Revisión sistemática y metaanálisis
Palabras clave:
Chronic Obstructive Pulmonary Disease, Surveys and Questionnaires, Reproducibility of Results (en)Enfermedad pulmonar obstructiva crónica, Encuestas y Cuestionarios, Reproducibilidad de los resultados (es)
Descargas
Introduction: The use of early screening questionnaires for chronic obstructive pulmonary disease (COPD) in primary health care could improve underdiagnosis. Several instruments are currently available, but there is scant information on their diagnostic performance.
Objective: To determine the validity of different questionnaires for COPD diagnosis.
Materials and methods: A systematic review and a meta-analysis of diagnostic test accuracy were carried out. A search of the literature published between July 1, 1997, and June 30, 2019 was performed in PubMed, EMBASE, and LILACS databases using MeSH and DeCS terms and the PICO strategy. Based on the inclusion and exclusion criteria, two reviewers selected the articles for complete analysis. Article quality was assessed using the QUADAS instrument.
Results: 19 articles were included for analysis. Overall results were: sensitivity: 68.1% (95%CI: 66.7% -69.4%); specificity: 64.9% (95%CI: 64.3-65.5); positive likelihood ratio: 2.024 (95%CI: 1.715-2.388); negative likelihood ratio: 0.407 (95%CI: 0.289-0.573); and receiver operating characteristic area under the curve (ROC AUC): 0.75. The COPD-PS questionnaire reported the highest performance with sensitivity of 0.673 (95%CI: 0.653-0.692), specificity of 0.663 (95%CI: 0.65.5- 0.651), and ROC AUC of 0.750. It was followed by LFQ with sensitivity of 0.840 (95%CI: 0.806-0.871), specificity of 0.312 (95%CI: 0.289-0.336), and ROC AUC of 0.730. Finally, CDQ had sensitivity of 0.798 (95%CI: 0.764-0.829), specificity of 0.517 (95%CI: 0.495-0.538), and ROC AUC of 0.727.
Conclusion: Clinical prediction instruments for COPD diagnosis have an acceptable performance. The COPD-PS, LFQ and CDQ questionnaires show a similar performance.
Introducción. El uso de cuestionarios de predicción clínica para el diagnóstico de la enfermedad pulmonar obstructiva crónica (EPOC) en atención primaria en salud podría mejorar el subdiagnóstico de esta enfermedad. Hoy en día existen varios instrumentos de este tipo; sin embargo, hay poca información sobre su rendimiento diagnóstico.
Objetivo. Determinar la validez del uso de los diferentes cuestionarios de predicción clínica para el diagnóstico de la EPOC.
Materiales y métodos. Se realizó una revisión sistemática con metaanálisis de prueba diagnóstica en las bases de datos PubMed, EMBASE y LILACS a partir de la estrategia PICO y utilizando términos MeSH y DeCS. Se incluyeron los estudios publicados entre julio 1 de 1997 y junio 30 de 2019. Dos revisores seleccionaron los artículos para análisis completo con base en los criterios de inclusión y exclusión. La calidad de los artículos se evaluó con el instrumento QUADAS.
Resultados. Se incluyeron 19 artículos para el análisis. En cuanto a la evaluación global de los cuestionarios se obtuvieron los siguientes datos: sensibilidad: 68.1% (IC95%: 66.7-69.4); especificidad: 64.9% (IC95%: 64.3-65.5); razón de verosimilitud positiva: 2.024 (IC95%: 1.715-2.388); razón de verosimilitud negativa: 0.407 (IC95%: 0.289-0.573) y el área bajo la curva de características del receptor (ACOR): 0.75. El cuestionario COPD-PS reportó el mayor rendimiento —sensibilidad: 0.673 (IC95%: 0.653-0.692), especificidad: 0.663 (IC95%: 0.655-0.671) y ACOR: 0.750—; seguido de LFQ —sensibilidad: 0.840 (IC95%: 0.806-0.871), especificidad: 0.312 (IC95%: 0.289-0.336) y ACOR: 0,730—, y CDQ —sensibilidad: 0.798 (IC95%: 0.764-0.829), especificidad: 0.517 (IC95%: 0.495-0.538) y ACOR: 0.727—.
Conclusión. Los instrumentos de predicción clínica para el diagnóstico de EPOC tienen un rendimiento aceptable, pues los valores de sensibilidad obtenidos a través de estos son superiores a los de la evaluación individual de la sintomatología respiratoria que se puede hacer a través de la historia clínica habitual.
Descargas
Citas
Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. European Resp J. 2019;53(5):1099164. https://doi.org/gf39d4.
Barrecheguren M, Pinto L, Mostafavi-Pour-Manshadi SMY, Tan WC, Li PZ, Aaron SD, et al. Identification and definition of asthma-COPD overlap: The CanCOLD study. Respirology. 2020;25(8):836-49. https://doi.org/fpnj.
Varmaghani M, Dehghani M, Heidari E, Sharifi F, Moghaddam SS, Farzadfar F. Global prevalence of chronic obstructive pulmonary disease: Systematic review and meta-analysis. East Mediterr Heal J. 2019;25(1):47-57. https://doi.org/fpnk.
Halbert RJ, Isonaka S, George D, Iqbal A. Interpreting COPD prevalence estimates: What is the true burden of disease?, Chest. 2003;123(5):1684-92. https://doi.org/fb9t7v.
World Health Organization (WHO). The top 10 causes of death. Geneva: WHO; 2018 [cited 2020 Aug 9]. Available from: https://bit.ly/3o0TPeL.
Labonte LE, Tan WC, Li PZ, Mancino P, Aaron SD, Benedetti A, et al. Undiagnosed chronic obstructive pulmonary disease contributes to the burden of health care use data from the CanCOLD study. Am J Respir Crit Care Med. 2016;194(3): 285-98. https://doi.org/f8xk7t.
Bednarek M, Maciejewski J, Wozniak M, Kuca P, Zielinski J. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax. 2008;63(5):402-7. https://doi.org/dvbj62.
Quach A, Giovannelli J, Chérot-Kornobis N, Ciuchete A, Clément G, Matran R, et al. Prevalence and underdiagnosis of airway obstruction among middle-aged adults in northern France: The ELISABET study 2011-2013. Respir Med. 2015;109(12):1553-61. https://doi.org/f729t2.
Martínez-Briseño D, Fernández-Plata MR, García-Sancho Figueroa MC, Pérez-Padilla R. La carga económica de la EPOC. Análisis de los costos a nivel internacional. Neumol Cir Tórax. 2011;70(2):118-26.
Pérez M, Puig-Peiró R, Aceituno S, Lizán L. Impacto económico de las exacerbaciones agudas en EPOC desde la perspectiva del SNS español. Rev Patol Respir. 2016;19(3):88-95.
Masa JF, Sobradillo V, Villasante C, Jiménez-Ruiz CA, Fernández-Fau L, Viejo JL, et al. Costes de la EPOC en España. Estimación a partir de un estudio epidemiológico poblacional. Arch Bronconeumol. 2004;40(2):72-9. https://doi.org/dtnqht.
Martinez FJ, Raczek AE, Seifer FD, Conoscenti CS, Curtice TG, D’Eletto T, et al. Development and Initial Validation of a Self-Scored COPD Population Screener Questionnaire (COPD-PS). COPD. 2008;5(2):85-95. https://doi.org/d6hww4.
Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:871-88. https://doi.org/f6zxdq.
Soler-Cataluña JJ, Martínez-García MÁ, Román-Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925-31. https://doi.org/fnstqc.
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2020 report). GOLD; 2020.
Colombia. Ministerio de Salud y Protección Social (MinSalud). Guía de práctica clínica basada en la evidencia para la prevención, diagnóstico, tratamiento y seguimiento de la Enfermedad Pulmonar Obstructiva Crónica (EPOC) en población adulta. Guía No. 28. Bogotá D.C.: MinSalud; 2014.
Tsukuya G, Matsumoto K, Fukuyama S, Crawford B, Nakanishi Y, Ichinose M, et al. Validation of a COPD screening questionnaire and establishment of diagnostic cut-points in a Japanese general population: The Hisayama study. Allergol Int. 2015;64(1):49-53. https://doi.org/f62wg9.
Stanley AJ, Hasan I, Crockett AJ, van Schayck OCP, Zwar NA. Validation of the COPD diagnostic questionnaire in an Australian general practice cohort: A cross-sectional study. Prim Care Respir J. 2014;23(1):92-7. https://doi.org/f5wf52.
Guirguis-Blake JM, Senger CA, Webber EM, Mularski RA, Whitlock EP. Screening for chronic obstructive pulmonary disease evidence report and systematic review for the US preventive services task force. JAMA. 2016;315(13): 1378-93. https://doi.org/cj48.
Yawn BP, Mapel DW, Mannino DM, Martinez FJ, Donohue JF, Hanania NA, et al. Development of the lung function questionnaire (LFQ) to identify airflow obstruction. Int J Chron Obstruct Pulmon Dis. 2010;5(1):1-10. https://doi.org/cfr859.
Dalal AA, Demuro-Mercon C, Lewis S, Nelson L, Gilligan T, McLeod L. Validation of alternate modes of administration of the lung function questionnaire (LFQ) in subjects with smoking history. Int J Chron Obstruct Pulmon Dis. 2010;5:425-34. https://doi.org/djrthk.
Hanania NA, Mannino DM, Yawn BP, Mapel DW, Martinez FJ, Donohue JF, et al. Predicting risk of airflow obstruction in primary care: Validation of the lung function questionnaire (LFQ). Respir Med. 2010;104(8):1160-70. https://doi.org/b7q7pr.
Llordés M, Zurdo E, Jaén Á, Vázquez I, Pastrana L, Miravitlles M. Which is the Best Screening Strategy for COPD among Smokers in Primary Care? COPD. 2017;14(1):43-51. https://doi.org/fpk8.
Arimura Y, Yamazaki S, Shirahama T, Matsukura S, Chiyotanda S, Nakazato M, et al. [Accuracy of COPD questionnaires in the general health check-up setting]. Nihon Kokyuki Gakkai Zasshi. 2008;46(9):693-9.
Spyratos D, Haidich AB, Chloros D, Michalopoulou D, Sichletidis L. Comparison of Three Screening Questionnaires for Chronic Obstructive Pulmonary Disease in the Primary Care. Respiration. 2017;93(2):83-9. https://doi.org/fpn3.
Bardapurkar S, Bardapurkar S, Gadge G. Can we diagnose COPD by just asking 8 questions? Eur Respir J. 2013;42(Suppl 57):1874.
Martinez FJ, Mannino D, Leidy NK, Malley KG, Bacci ED, Barr RG, et al. A new approach for identifying patients with undiagnosed chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(6):748-56. https://doi.org/f9tp66.
Londhe J, Apte K, Barne M, Salvi S. CAPTURE: A screening tool for chronic obstructive pulmonary disease or obstructive airway disease? Am J Respir Crit Care Med. 2018;197(2):272. https://doi.org/fpn4.
Miravitlles M, Koblizek V, Esquinas C, Milenkovic B, Barczyk A, Tkacova R, et al. Determinants of CAT (COPD Assessment Test) scores in a population of patients with COPD in central and Eastern Europe: The POPE study. Respir Med. 2019;150:141-8. https://doi.org/fpn5.
Gabler NB, Duan N, Liao D, Elmore JG, Ganiats TG, Kravitz RL. Dealing with heterogeneity of treatment effects: Is the literature up to the challenge? Trials. 2009 ;10(1):43. https://doi.org/btz79d.
Fernandez y Garcia E, Nguyen H, Duan N, Gabler NB, Kravitz RL. Assessing Heterogeneity of Treatment Effects: Are Authors Misinterpreting Their Results? Health Serv Res. 2010;45(1):283-301. https://doi.org/bmfch8.
Haroon S, Jordan R, Takwoingi Y, Adab P. Diagnostic accuracy of screening tests for COPD: A systematic review and meta-analysis. BMJ Open. 2015;5(10):e008133. https://doi.org/f88ndf.
López-Varela MV, Montes-de Oca M, Rey A, Casas A, Stirbulov R, Di Boscio V. Development of a simple screening tool for opportunistic COPD case finding in primary care in Latin America: The PUMA study. Respirology. 2016;21(7): 1227-34. https://doi.org/f85fnw.
Mahesh PA, Jayaraj BS, Prahlad ST, Chaya SK, Prabhakar AK, Agarwal AN, et al. Validation of a structured questionnaire for COPD and prevalence of COPD in rural area of Mysore: A pilot study. Lung India. 2009;26(3):63-9. https://doi.org/ftv2dd.
Murgia N, Brisman J, Claesson A, Muzi G, Olin AC, Torén K. Validity of a questionnaire-based diagnosis of chronic obstructive pulmonary disease in a general population-based study. BMC Pulm Med. 2014;14(1):49. https://doi.org/gb3k6w.
Calverley PMA, Nordyke RJ, Halbert RJ, Isonaka S, Nonikov D. Development of a population-based screening questionnaire for COPD. COPD. 2005;2(2):225-32.
Kotz D, Nelemans P, Van Schayck CP, Wesseling GJ. External validation of a COPD diagnostic questionnaire. Eur Respir J. 2008;31(2):298-303. https://doi.org/dktw68.
Mintz ML, Yawn BP, Mannino DM, Donohue JF, Hanania NA, Grellet CA, et al. Prevalence of airway obstruction assessed by lung function questionnaire. Mayo Clin Proc. 2011;86(5): 375-81. https://doi.org/d8ftb9.
Kim JK, Lee CM, Park JY, Kim JH, Park S-H, Jang SH, et al. Active case finding strategy for chronic obstructive pulmonary disease with handheld spirometry. Medicine (Baltimore). 2016;95(50):e5683. https://doi.org/fpmc.
Price DB, Tinkelman DG, Nordyke RJ, Isonaka S, Halbert RJ. Scoring system and clinical application of COPD diagnostic questionnaires. Chest. 2006;129(6):1531-9. https://doi.org/bstdzb.
Frith P, Crockett A, Beilby J, Marshall D, Attewell R, Ratnanesan A, et al. Simplified COPD screening: Validation of the PiKo-6® in primary care. Prim Care Respir J. 2011;20(2):190-8. https://doi.org/cpd3z8.
Yoshimoto D, Nakano Y, Onishi K, Hagan G, Jones P. The relationship between the COPD assessment test score and airflow limitation in Japan in patients aged over 40 years with a smoking history. Int J Chron Obstruct Pulmon Dis. 2014;9:1357-63. https://doi.org/fpmg.
Sichletidis L, Spyratos D, Papaioannou M, Chloros D, Tsiotsios A, Tsagaraki V, et al. A combination of the IPAG questionnaire and PiKo-6® flow meter is a valuable screening tool for COPD in the primary care setting. Prim Care Respir J. 2011;20(2):184-9. https://doi.org/frtj3n.
Freeman D, Nordyke RJ, Isonaka S, Nonikov DV, Maroni JM, Price D, et al. Questions for COPD diagnostic screening in a primary care setting. Respir Med. 2005;99(10):1311-8. https://doi.org/d6vd5v.
Buffels J, Degryse J, Heyrman J, Decramer M. Office spirornetry significantly improves early detection of COPD in general practice: The DIDASCO Study. Chest. 2004;125(4): 1394-9. https://doi.org/fpv558.
Schapira RM, Schapira MM, Funahashi A, Mcauliffe TL, Varkey B. The Value of the Forced Expiratory Time in the Physical Diagnosis of Obstructive Airways Disease. JAMA. 1993;270(6):731-6.
Straus SE, McAlister FA, Sackett DL, Deeks JJ. Accuracy of history, wheezing, and forced expiratory time in the diagnosis of chronic obstructive pulmonary disease. J Gen Intern Med. 2002;17(9):684-8. https://doi.org/dzdmv6.
Straus SE, McAlister FA, Sackett DL, Deeks JJ. The accuracy of patient history, wheezing, and laryngeal measurements in diagnosing obstructive airway disease. CARE-COAD1 Group. Clinical Assessment of the Reliability of the Examination-Chronic Obstructive Airways Disease. JAMA. 2000;283(14):1853-7. https://doi.org/fvc8x8.
King DK, Thompson BT, Johnson DC. Wheezing on maximal forced exhalation in the diagnosis of atypical asthma. Lack of sensitivity and specificity. Ann Intern Med. 1989;110(6): 451-5. https://doi.org/fpn6.
Holleman DR, Simel DL, Goldberg JS. Diagnosis of obstructive airways disease from the clinical examination. J Gen Intern Med. 1993;8(2):63-8. https://doi.org/br72pr.
Nelson SB, LaVange LM, Nie Y, Walsh JW, Enright PL, Martinez FJ, et al. Questionnaires and pocket spirometers provide an alternative approach for COPD screening in the general population. Chest. 2012;142(2):358-66. https://doi.org/fxqp6q.
Represas-Represas C, Botana-Rial M, Leiro-Fernández V, González-Silva AI, del Campo-Pérez V, Fernández-Villar A. Validación del dispositivo portátil COPD-6 para la detección de patologías obstructivas de la vía aérea. Arch Bronconeumol. 2010;46(8):426-32. https://doi.org/fmwxrx.
Pierce R. Spirometry: an essential clinical measurement. Aust Fam Physician. 2005;34(7):535-9.
Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155(3):179-91. https://doi.org/9mc.
Malone DC, Hines LE, Graff JS. The good, the bad, and the different: A primer on aspects of heterogeneity of treatment effects. J Manag Care Pharm. 2014;20(6):555-63. https://doi.org/f6f9h4.
Kent DM, Rothwell PM, Ioannidis JPA, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: A proposal. Trials. 2010;11(1):85. https://doi.org/cmpxkf.
Licencia
Derechos de autor 2021 Revista de la Facultad de Medicina
Esta obra está bajo una licencia Creative Commons Reconocimiento 3.0 Unported.
-
